News Image

Madrigal Pharmaceuticals Inc (NASDAQ:MDGL) Beats Q2 2025 Revenue Estimates and Narrows Losses on Strong Rezdiffra Sales

By Mill Chart

Last update: Aug 5, 2025

Madrigal Pharmaceuticals Inc (NASDAQ:MDGL) Surpasses Revenue Estimates in Q2 2025, Narrows Losses

Madrigal Pharmaceuticals Inc (NASDAQ:MDGL) reported its second-quarter 2025 financial results, delivering a revenue beat while narrowing its losses compared to analyst expectations. The company’s performance was driven by strong sales of its flagship drug, Rezdiffra™ (resmetirom), which continues to gain traction in the treatment of metabolic dysfunction-associated steatohepatitis (MASH).

Key Financial Highlights

  • Revenue: Reported $212.8 million in Q2 2025, significantly exceeding the consensus estimate of $164.7 million. This represents a robust commercial performance for Rezdiffra, which was approved earlier this year.
  • Earnings Per Share (EPS): Posted a loss of $1.90 per share, an improvement over the estimated loss of $3.71 per share. The narrower-than-expected loss suggests better cost management and higher-than-anticipated revenue contributions.
  • Patient Adoption: As of June 30, 2025, more than 23,000 patients were on Rezdiffra, indicating strong uptake since its launch.

Market Reaction

The market responded positively to the earnings release, with shares rising 12.8% in pre-market trading. This suggests investor optimism around the company’s revenue growth and improving financial trajectory. Over the past month, the stock has gained 7.9%, though it remains relatively flat over the past two weeks (-5.7%) and slightly up over the past week (+0.06%).

Looking Ahead

Analysts project full-year 2025 sales of approximately $696.5 million, with Q3 2025 sales expected to reach $185.7 million. The company did not provide explicit guidance in its press release, but the strong Q2 performance may lead to upward revisions in future estimates.

Corporate Updates

Madrigal highlighted ongoing progress with its Phase III outcomes trial for Rezdiffra in treating compensated MASH cirrhosis (stage F4c). The drug remains central to the company’s growth strategy, with continued expansion in patient access and market penetration.

For a deeper dive into Madrigal’s earnings and analyst estimates, visit the earnings page.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. Investors should conduct their own research or consult a financial advisor before making any decisions.

MADRIGAL PHARMACEUTICALS INC

NASDAQ:MDGL (8/25/2025, 8:00:01 PM)

After market: 412.23 0 (0%)

412.23

-2.45 (-0.59%)



Find more stocks in the Stock Screener

MDGL Latest News and Analysis

Follow ChartMill for more